Cytokinetics Files 8-K/A Amendment
Ticker: CYTK · Form: 8-K/A · Filed: Sep 8, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K/A |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Cytokinetics filed an amendment to its 8-K, updating financial statements and exhibits.
AI Summary
Cytokinetics, Inc. filed an 8-K/A on September 8, 2025, to amend a previous filing. The amendment pertains to financial statements and exhibits, with the earliest event reported being August 31, 2025. The company is headquartered at 350 Oyster Point Boulevard, South San Francisco, California.
Why It Matters
This filing is an amendment to a previous report, indicating updates or corrections to financial statements and exhibits, which could be relevant for investors assessing the company's financial health.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or financial distress.
Key Players & Entities
- Cytokinetics, Inc. (company) — Registrant
- 350 Oyster Point Boulevard (location) — Principal Executive Offices
- South San Francisco, California (location) — Principal Executive Offices
- August 31, 2025 (date) — Date of earliest event reported
- September 8, 2025 (date) — Filing Date
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, specifically concerning financial statements and exhibits.
What is the earliest event date reported in this filing?
The earliest event reported is August 31, 2025.
What is Cytokinetics, Inc.'s principal executive office address?
The principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California, 94080.
When was this 8-K/A filing submitted to the SEC?
This filing was submitted on September 8, 2025.
What is the standard industrial classification for Cytokinetics, Inc.?
The standard industrial classification for Cytokinetics, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2025-09-08 17:02:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20250831.htm (8-K/A) — 43KB
- cytk-ex99_1.htm (EX-99.1) — 80KB
- img114956760_0.jpg (GRAPHIC) — 23KB
- img114956760_1.jpg (GRAPHIC) — 117KB
- 0000950170-25-113599.txt ( ) — 435KB
- cytk-20250831.xsd (EX-101.SCH) — 25KB
- cytk-20250831_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On August 31, 2025, Cytokinetics, Incorporated announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of aficamten on cardiac structure and function from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), which was simultaneously published in the Journal of the American College of Cardiology, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation (AF) associated with aficamten, which was simultaneously published in Heart Rhythm. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This Current Report on Form 8-K/A is being filed because the original Form 8-K filed on September 2, 2025 was missing a hyperlink to the press release that is furnished as Exhibit 99.1 to this Current Report on Form 8-K/A.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 99.1 Press Release dated August 31, 2025 . 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: September 8, 2025 By: /s/ John Faurescu SVP, Deputy General Counsel & Secretary